DiaSorin – AGM 10 june 2020
The following concerns arise over DiaSorin's remuneration policy:
- the vesting of stock options does not depend on any performance conditions, does not depend on any performance conditions,
- both the annual and long-term cash incentives depend on only one absolute performance indicator (EBIT),
- early vesting of incentives and the CEO's indemnity in the event of a change in control (equal to 3 years of cash remuneration) are contrary to our guidelines,
- discretionary bonuses are allowed and no clawback mechanisms are provided.
Therefore, we recommend shareholders to oppose the remuneration policy (binding vote in item 2.1), the remuneration paid in 2019 (advisory vote in item 2.2), the 2020 Stock Option Plan (item 3) and share buyback programme to implement the Stock Option Plan (item 4).
Diasorin is engaged in the market for in vitro diagnostics. Co. is developing, producing and commercializing diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. In the immunodiagnostics market segment, Co. develops, produces and markets immunoreagent kits based on three different detection techniques. In the molecular diagnostics segment, Co. supplies end laboratories with an automated solution to perform the three steps required for the final diagnostic result.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.